✦ LIBER ✦

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

✍ Scribed by Anique Ducharme; Karl Swedberg; Marc A. Pfeffer; Alain Cohen-Solal; Christopher B. Granger; Aldo P. Maggioni; Eric L. Michelson; John J.V. McMurray; Lars Olsson; Jean L. Rouleau; James B. Young; Bertil Olofsson; Margareta Puu; Salim Yusuf

Book ID: 116190314
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 238 KB
Volume: 152
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2005.06.036

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The data monitoring experience in the Ca

The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program

✍ Stuart Pocock; Duolao Wang; Lars Wilhelmsen; Charles H. Hennekens 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 110 KB

Atrial Fibrillation and Risk of Clinical

Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction: Results From the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program

✍ Lars G. Olsson; Karl Swedberg; Anique Ducharme; Christopher B. Granger; Eric L. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 431 KB

Effects of Candesartan on Mortality and

Effects of Candesartan on Mortality and Morbidity in Patients With Chronic Heart Failure: The CHARM-Overall Programme

✍ Sricharan Kantipudi; Atul Khasnis 📂 Article 📅 2004 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 117 KB

Effects of candesartan on mortality and

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

✍ Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John JV McMurr 📂 Article 📅 2003 🏛 The Lancet 🌐 English ⚖ 129 KB

Effect of candesartan on New York Heart

Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programme

✍ E. O’Meara; S. Solomon; J. McMurray 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 36 KB

Days alive and out of hospital and the p

Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

✍ Cono A. Ariti; John G.F. Cleland; Stuart J. Pocock; Marc A. Pfeffer; Karl Swedbe 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 229 KB